The proof-of-principle experiments using CpG-siRNAs to target tumorigenic NF-κB/RELA and STAT3 signaling in xenotransplanted TLR9+ prostate tumors confirmed therapeutic efficacy of such strategy. This evidence concerns the gene STAT3 and prostate neoplasm.